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A b s t r a c t 27 
Meningococcal epidemiology may change unpredictably and typing of isolates of 28 
Neisseria meningitidis is crucial for the surveillance of invasive meningococcal 29 
disease (IMD). Few data are available of the meningococcal epidemiology in 30 
countries of North Africa. We aimed to explore the invasive meningococcal isolates 31 
from the Casablanca region in Morocco. We used whole genome sequencing (WGS) 32 
to characterize 105 isolates from this region during the period 2011–2016. Our data 33 
showed that the majority (n=100) of the isolates belonged to serogroup B. The 34 
genotyping of most of these isolates (n=62) belong to the sequence type (ST-33) of 35 
the clonal complex cc32. They also showed the same PorA and FetA markers and 36 
clustered together on the basis of WGS phylogenic analysis and seemed to correspond 37 
to an expansion of local isolates in the Casablanca region as also reported with similar 38 
isolates in several other countries in the world. 39 
These data suggest that serogroup B isolates may predominate in Morocco. They also 40 
have important impact on designating vaccination strategies.   41 
 42 
 43 
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 45 
 46 
 47 
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Introduction 49 
Neisseria meningitidis (the meningococcus), a Gram negative capsulated bacterium, 50 
is the causative agent of invasive meningococcal disease (IMD). IMD is characterized 51 
mainly by meningitis and/or septicemia but other clinical forms are also described (1). 52 
N. meningitidis causes globally an estimated 500000 cases of invasive meningococcal 53 
disease (IMD) per year with 10% fatality rate as well as permanent sequelae among 54 
survivors(2). Meningococci are classified into 12 serogroups based on biochemical 55 
properties of their capsular polysaccharides but 6 of them (A, B, C, W, Y and X) are 56 
responsible for almost all the disease worldwide (3). Capsular polysaccharide-based 57 
conjugate vaccines are available against serogroups A, C, W and Y while 58 
proteins-based vaccines are available against isolates of serogroup B (3).  59 
The incidence of IMD varies worldwide with low incidence in industrialized 60 
countries between 0.3–4 cases per 100,000 population but the incidence can approach 61 
1000 per 100,000 during epidemics in countries of the sub-Saharan Africa(4). Indeed, 62 
IMD occurs either as sporadic cases with occasional outbreaks in the industrialized 63 
countries such as in Europe. However, major epidemics occur periodically in the 64 
African meningitis belt, a region that spans countries between Senegal in the west and 65 
Ethiopia in the east (5). The distribution of serogroups also varies in space and time. 66 
Serogroup B predominates in Europe, North America and Australasia (6). Periodic 67 
epidemics of meningococcal disease occurred in the meningitis belt that have been 68 
caused by serogroup A but serogroup A decreased in the meningitis belt since the 69 
introduction of the conjugate vaccine against isolates of serogroup A but isolates 70 
belonging to serogroups C, W and X emerged (4, 7-9). Moreover, serogroup W seems 71 
to undergo a worldwide increase since 2013 (10). Few data are available form North 72 
Africa countries (6, 11) and IMD is mainly considered as travel disease linked to the 73 
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Hajj and Umrah pilgrimages (12). Previous data from the Casablanca region in 74 
Morocco obtained between January 1992 and September 2000 showed predominance 75 
(75.5%) of serogroup B isolates with strains of the phenotype 76 
(serogroup:serotype:serosubtype) B:4:P1.15 representing 74.8% of all serogroup B 77 
isolates (13). We aimed in this work to follow the recent evolution of IMD in 78 
Casablanca region that represents 20% of the population of Morocco using whole 79 
genome sequencing (WGS) approach in order to provide more genetic resolution on 80 
the isolates and their relationship to other isolates that are currently circulating 81 
worldwide.  82 
 83 
 84 
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Materials and Methods 95 
Ethical Statement 96 
Isolates were obtained as part of routine activity of the Bacteriological laboratory at 97 
Hospital Ibn Rochd in Casablanca, and were analyzed anonymously for the 98 
epidemiological surveillance and control of communicable disease in the Moroccan 99 
Community. Ethical approval and informed consent were thus not required. A case of 100 
IMD was defined as the recovery of an isolate of N. meningitidis or meningococcal 101 
DNA from a normally sterile body site, such as blood, cerebrospinal fluid (CSF), joint 102 
aspirates. 103 
Characterization of the isolates 104 
PCR was used to confirm suspected cases with negative culture (N=45) as previously 105 
described (14). The 105 cultured invasive isolates available from cases of IMD at the 106 
Ibn Rochd hospital for the period 2011-2016. All isolates were cultured on GCB 107 
medium plated supplemented with Kellogg supplements (15). Isolates were identified 108 
on the basis of typical morphology of colonies, Gram stain, oxidase test and API NH 109 
test (bioMerieux, Marcy l’Etoile, France), according to the manufacturer’s 110 
instructions. Antibiotic susceptibility testing was performed using Etest Minimal 111 
inhibitory concentrations (MICs) for Penicillin, amoxicillin, ciprofloxacin and 112 
Ceftriaxone,  were determined by the E-test (Oxoid) methods according to 113 
manufacturers’ instructions [15] and interpreted according to the latest EUCAST 114 
guidelines, as previously recommended and described for N. meningitidis (16).  115 
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The isolates were sent to the Institut Pasteur, Paris, France for WGS. Serogrouping 116 
and genogrouping were performed as previously described (14). Genomic DNA was 117 
extracted using the Roche MagNA Pure 96 system (Roche, Pleasanton CA 9, USA). 118 
Sequencing was performed by Illumina HiSeq 2000 sequencer (Illumina, San Diego, 119 
CA, USA) and assembled as previously described (17). Sequences are available 120 
through the PubMLST database which runs on the Bacterial Isolate Genome 121 
Sequence Database (BIGSdb) platform (18). WGS data were analyzed on the 122 
PubMLST to extract sequence type (ST) and clonal complexes according to the 123 
multilocus sequence typing analysis. Other alleles corresponding to genes of interest 124 
for antibiotic susceptibility were also extracted. WGS data were also analyzed using a 125 
“gene-by-gene” approach available through the PubMLST Genome Comparator tool 126 
using  N. meningitidis core genome MLST (cgMLST) v1.0 that includes 1605 core 127 
loci (18). SplitsTree4 (version 4.13.1) was used to visualize the resulting distance 128 
matrices as Neighbor-net networks (19). The IDs of all these isolates are given in the 129 
supplementary Table to allow retrieving of WGS sequence in FASTA formats. 130 
 131 
 132 
 133 
 134 
 135 
 136 
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Results 138 
Description of cases of cases of IMD 139 
In Morocco, notification of clinically suspected cases of IMD should be reported to 140 
the regional health authority and Case notification forms are sent to the Department of 141 
Epidemiology, Ministry of Health. The annual incidence is 2 to 3.6 per 100,000 142 
inhabitants with 700-850 suspected cases per year fro the entier country. The Ibn 143 
Rochd University Hospital usually receives cases from the Casablanca region (about 144 
20% of the entire country population). The surveillance for IMD is performed under 145 
the national recommendations mentioned above. Cultured bacterial isolates and 146 
samples can be sent to the Institut Pasteur of Morocco in Casablanca for identification 147 
and typing. 148 
One hundred and forty five suspected meningococcal cases were reported and 149 
confirmed by cultured and/or PCR in Casablanca between 2011 and 2016. These 150 
cases were estimated to correspond to 25% to 40% des suspected reported cases in 151 
Casablanca. Of these 145 biologically confirmed cases, 40 (27.6%) were primary 152 
clinical materials (CSF) with no positive culture and were confirmed by PCR and 105 153 
(72.4%) of viable cultured isolates. Most of the isolates (71%) were from CSF and 154 
29% from blood. 155 
We analyzed 105 isolates from Casablanca between 2011 and 2016. The age of 156 
patients ranged from 3 day to 61 years the median age is 3 years. The majority of 157 
isolates belonged to serogroup B (100 isolates; 95% for the entire period). One isolate 158 
was of serogroup C and two isolates of serogroup W and two isolates of serogroup Y. 159 
The annual distribution of isolates during this period according to serogroups is 160 
depicted in Fig.1. We detected 19% of the isolates with reduced susceptibility to 161 
penicillin G (0.12 mg/L ≤ MIC ≤ 0.25 mg/L). 162 
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 163 
Analysis of the genetic markers of the isolates 164 
Data on the MLST were extracted from WGS and isolates were grouped into clonal 165 
complexes (Fig. 2A). Twenty-five different sequence types (STs) were identified 166 
among the isolates that were grouped into 10 clonal complexes (cc). However, 78 167 
isolates (74% of all tested isolates) belonged to one clonal complex, the cc32. ST-33, 168 
that belonged to the cc32, was the most frequent ST (n=62 isolates) in the cc32 in in 169 
the collection tested in Casablanca. Few isolates differed from ST-33 by one locus 170 
(single locus variants) or by two loci (double locus variants) (Fig. 2B).  171 
The isolates harbored several alleles of penA encoding the penicillin binding protein2 172 
(PBP2). Alterations of PBP2 were directly linked to the reduction of susceptibility to 173 
penicillin G in meningococci (20). Four highly related alleles (penA1, penA2, penA3 174 
and penA22) were found in 85 isolates that were previously described to correspond 175 
to the penicillin G-susceptible isolates (20). Twenty isolates harbored diverse and 176 
altered alleles (penA9, penA19, penA33, penA35, penA217, penA295, penA709 and 177 
penA710) were previously described to correspond to isolates with reduced 178 
susceptibility to penicillin G. Indeed, the isolates harboring modified penA alleles 179 
correlated with MIC values of penicillin G.  180 
There were several fines types (the combination of variable regions VR1 and VR2 of 181 
PorA and the variable region of FetA) but the finetype P1.19,15:F5-1 was the most 182 
frequent and was represented by 58 isolates that were all of serogroup B and cc32. 183 
These isolates were present throughout the study period (2011-2016).  184 
The unique serogroup C isolate belonged to the ST-3327 of the cc865. The two 185 
serogroup Y isolates were different and belonged to ST-1627 (cc167) and ST-1466 186 
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(cc174). The two serogroup W isolates were of ST-11 and ST-13257 that both 187 
belonged to the cc11 as ST-13257 was single locus variant of the ST-11. 188 
 189 
Genomic analysis of isolates 190 
To describe the relationships of the isolates, all the 105 cultured isolates (for the 191 
period 2010-2016) were subjected to cgMLST analysis using the BIGSdb tools in the 192 
PubMLST database (see Materials and Methods). The isolates grouped into several 193 
lineages. The major cluster corresponded to the cc32 isolates that were quite separated 194 
from the other serogroup B isolates (Fig. 3A). The isolates of serogroup 195 
B:P1.19,15:F5-1:cc32 were highly related, we therefore compared by cgMLST the 196 
relationships of these isolates from Morocco to all other isolates sharing the same 197 
combination and that were available on the PubMLST (accessed on 26/12/2017). In 198 
addition to the 58 isolates from Morocco, there were 69 other isolates between 1976 199 
and 2017 and were from the UK, France, Brazil, Cuba, Italy, Slovenia, South Africa, 200 
Canada, Denmark, Greece, Ivory Coast and Switzerland. The phylogenetic trees 201 
showed clear clustering of the Moroccan isolates distinctly from the isolates from 202 
other countries. Only few isolates from France and the UK were clustered with the 203 
Moroccan isolates (Fig. 3B). Isolates from Casablanca region harbored the genes 204 
encoding the antigens of the vaccines against serogroup B (Supplementary Table). 205 
The serogroup W/cc11 isolates were compared to other W/cc11 isolates that we have 206 
recently published in France and that belonged to the two major sublineages: the 207 
“Anglo-French-Hajj” sub-lineage and “South American-UK” sub-lineage with its two 208 
variants the “original UK strain” and the “UK 2013-strain (21, 22). This analysis 209 
clustered the two Moroccan isolates within the “Anglo-French-Hajj” (Fig. 3B). 210 
 211 
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Discussion 212 
This report used WGS analysis as a tool for complete characterization of invasive 213 
meningococcal isolates from the Casablanca region of Morocco. Our data showed the 214 
majority of the isolates were of serogroup B in agreement with a previous report (13). 215 
Recent data from Tunisia also suggested that serogroup B predominates in the 216 
country between 1998 and 2013 (23). Serogroup B isolates were also reported in 217 
Algeria between 1992-2001 (24). A shift from a serogroup A to serogroup B was 218 
noted in Egypt since 1991(25). However, the data remained scarce from North Africa 219 
with little molecular typing data.  220 
The previous work on the isolate in Casablanca region reported the phenotype P1.15 221 
for the isolate of serogroup B (13) that is in agreement with our findings on the typing 222 
of PorA (P1.19,15). Moreover, the WGS data were also available on for one group 223 
B/cc32 isolate from Morocco from 1994 on the PubMLST database (ID 26047) and 224 
clustered together with the recent isolates (26) (Figure 2). Our Data suggest the 225 
persistence of these isolates in the region and may further suggest a recent clonal 226 
 expansion of these isolates with most of the isolates belonging to the major sequence 227 
type (ST-33) and few single locus and double locus variants. Of interest, the cgMLST 228 
analysis showed that these isolates seem to differ from related isolates reported in 229 
other countries suggesting an expansion of a local strain in the Casablanca region. 230 
These related isolates were responsible for large expansion as was reported in Cuba 231 
and Brazil and lead to vaccination campaigns (27). The availability of protein-based 232 
vaccines may provide a possible strategy to control the expansion of those isolates. 233 
These isolates harbor genes encoding the vaccine antigens. However, expression 234 
assays are required to confirm coverage (28).  One limitation of our data is their 235 
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representativeness, but few exhaustive data are available due to limitations in 236 
reporting, diagnosis and typing (6).     237 
The use of the WGS approach provide a thorough understanding of the circulating 238 
meningococcal isolates that provide powerful tools for high resolution in 239 
epidemiological surveillance and should help decision making to tailor vaccination 240 
strategies.241 
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Legends of figures 382 
Figure1. Distribution of the isolates of the study according to their serogroups and 383 
year of isolation. 384 
Figure2. (A) Distribution of the isolates of the study according to their serogroups 385 
and clonal complexes. (B) BURST analysis of the isolates of the clonal complex cc32 386 
on the basis of the seven loci of the MLST. The most frequent sequence type (ST-33) 387 
is in the central circle (black). The middle circle (red) represents the single locus 388 
variants for the ST-33 and the outer circle (bleu) represents the double locus variant 389 
from the ST-33 390 
Figure 3. (A) Neighbor-net phylogenetic network of all invasive cultured isolates 391 
received of the study from the region of Casablanca, Morocco (2011-2016). The tree 392 
was drawn on the basis of cgMLST. The 10 clonal complexes and the corresponding 393 
serogroup of the isolates are indicated. (B) Neighbor-net phylogenetic network of all 394 
serogroup B isolates showing the finetype P.19,15:F5-1 in the PubMLST database: 58 395 
isolates from Morocco in addition to 69 other isolates between 1976-2017 and were 396 
from the UK, France, Brazil, Cuba, Italy, Slovenia, South Africa, Canada, Denmark, 397 
Greece, Ivory Coast and Switzerland. The isolates from Morocco 1994 is indicated by 398 
an arrow (ID 26047) (C) Neighbor-net phylogenetic network of the two serogroup W 399 
isolates from our collection (black circle) B depicted within the tree of all invasive 400 
serogroup W isolates from France (period 2010-2016). Cases are classified in three 401 
groups using WGS data: “original UK strain”, “UK 2013-strain” and the 402 
Anglo-French-Hajj. 403 
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